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Background and purpose: 5-lipoxygenase (5-LO) is the key enzyme in leukotriene (LT) biosynthesis from arachidonic acid
(AA). Here, we examined the role of the 5-LO-product, cysteinyl-LT (Cys-LT), with a 5-LO inhibitor (zileuton) and a Cys-LT,
receptor antagonist (montelukast), in the inflammatory response and tissue injury associated with spinal cord injury (SCI).
Experimental approach: SCI was induced in mice by the application of vascular clips to the dura via a two-level T6 to T7
laminectomy for 1 min. Cord inflammation was assessed histologically and by measuring inflammatory mediators (ELISA) and
apoptosis by annexin V, TUNEL, Fas ligand staining and Bax and Bcl-2 expression (immunohistochemistry and western blots).
Motor function in hindlimbs was assessed by a locomotor rating scale, for 10 days after cord injury.
Key results: SCI in mice resulted in tissue damage, oedema, neutrophil infiltration, apoptosis, tumour necrosis-a (TNF-a) and
cyclooxygenase-2 (COX-2) expression, prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) production, and extracellular signal-
regulated kinase 1/2 (ERK1/2) phosphorylation in injured tissue. Treatment of the mice with zileuton or montelukast reduced
the spinal cord inflammation and tissue injury, neutrophil infiltration, TNF-a, COX-2 and pERK1/2 expression, PGE2 and LTB4
production, and apoptosis. In separate experiments, zileuton or montelukast significantly improved the recovery of limb
function over 10 days.
Conclusions and implications: Zileuton and montelukast produced a substantial reduction of inflammatory events associated
with experimental SCI. Our data underline the important role of 5-LO and Cys-LT in neurotrauma.
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Introduction
Traumatic spinal cord injury (SCI) is an unexpected,
catastrophic event, the consequences of which often persists
for the life of the patient and influences not only the patient
but also family members and society (Stover and Fine, 1987).
It is known that SCI initiates a cascade of cellular and
molecular events (Tator, 1995; Xu et al., 2001; Hausmann,
2003; Beattie, 2004; Gris et al., 2004) and that a progressive
neuronal injury results from a combination of secondary
injury factors, including ischaemia, biochemical alterations,
apoptosis, excitotoxicity, neurotransmitter accumulation
and lipid peroxidation/free radical injury (Carlson and
Gorden, 2002). It is believed that inflammatory and immune
responses are the major component of secondary injury and
play a central role in regulating the pathogenesis of acute
and chronic SCI (Anderson, 2002; Bethea and Dietrich, 2002;
Yang et al., 2004). Studies, mostly carried out in vitro, have
disclosed a series of events related to the occurrence of
neuronal damage following SCI: mitogen-activated protein
kinase (MAPK) activation, initiation of inflammatory re-
sponses (liberation of pro-inflammatory mediators, such as
nitric oxide, tumour necrosis factor-a (TNF-a), prostaglan-
dins (PGs) and leukotrienes (LTs)) and degeneration of
neurons. In particular, it has been reported that phosphory-
lation of extracellular signal-regulated kinase 1/2 (ERK1/2)
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results in expression of genes mediating the inflammatory
responses, such as those encoding for TNF-a and cyclooxy-
genase-2 (COX-2) (Jung et al., 2005). Moreover, although the
mechanisms are not fully understood, inflammatory re-
sponses leading to endothelial damage may be involved
in the secondary injury process (Demopoulos et al.,
1978; Hamada et al., 1996; Taoka et al., 1997). In fact,
neutrophils are the first leucocytes to arrive within the
injured spinal cord (Carlson et al., 1998; McTigue et al., 1998)
and can cause endothelial cell injury through the
liberation of several inflammatory mediators (Xu et al.,
1990), such as cytokines (Profyris et al., 2004), nitric oxide
(Dietrich et al., 2004), COX-2 (Adachi et al., 2005) and
5-lipoxygenase (5-LO) metabolites (Suttorp et al., 1987; Xu
et al., 1990; Mitsuhashi et al., 1994). In particular, it has been
demonstrated that neutrophil infiltration in SCI is propor-
tional to both the magnitude of trauma and the amount of
leukotriene B4 (LTB4), a product of 5-LO (Suttorp et al., 1987;
Xu et al., 1990). An enhanced synthesis of leukotriene C4
(LTC4) in the injured spinal cord has also been reported
(Mitsuhashi et al., 1994; Nishisho et al., 1996). For
example, in the canine model, a significant increase in
LTC4 levels was observed and there was a good correlation
between levels of LTC4 in cerebrospinal fluid and the
severity of neurological damage. Moreover, the time-depen-
dent change in LTC4 concentrations in seven patients with
SCI was similar to that observed in the canine model
(Nishisho et al., 1996). Other 5-LO products are also involved
in SCI, as 5-hydroxyeicosatetraenoic acid levels increase
after experimental SCI in rabbits and it has been hypothe-
sized that this increase may be involved in the pathophy-
siology of spinal cord trauma (Jacobs et al., 1987; Shohami
et al., 1987).
One of the reasons why most of the treatments utilized in
preclinical studies (Leker and Shohami, 2002) have had
limited success in clinical trials is because of the complexity
of the secondary degenerative response. In fact, many
treatments affect only one aspect of this response, and a
successful treatment will probably have to target several of
these mechanisms (King et al., 2006). A number of experi-
mental animal models have been developed to simulate
the pathophysiology of acute clinical spinal cord compres-
sion in humans (Beattie et al., 2002). The most commonly
used model is the compression model; in this model, injury
is induced by applying either a weight or an aneurysm
clip to the spinal cord (Tator and Fehlings, 1991).
This experimental procedure is closer to the human situation
in respect to the contusion model, since it replicates
the persistence of cord compression that is com-
monly observed in human SCI (Tator, 1995). We
have demonstrated in the compression model, by the use
of 5-LO knockout mice, that the absence of this enzyme
caused a substantial reduction of inflammatory events
characteristic of SCI (Genovese et al., 2005). As suppression
of enzyme activity by gene deletion can give rise to
compensatory mechanisms, we decided to investigate the
role of 5-LO products using the same model of SCI. In
particular, we examined cysteinyl-LTs (Cys-LTs) with a 5-LO
inhibitor (zileuton) and a Cys-LT1 receptor antagonist
(montelukast).
Methods
Animals
Animal care was in compliance with Italian regulations on
protection of animals used for experimental and other
scientific purpose (Ministerial Decree 116192) as well as
with the European Economic Community regulations
(Official Journal of E.C. L 358/1 12/18/1986). Male adult
CD1 mice (25–30 g, Harlan Nossan, Milan, Italy) were
housed in a controlled environment and provided with
standard rodent chow and water.
Spinal cord injury
Mice were anaesthetized using chloral hydrate (40 mg kg1
body weight). A longitudinal incision was made on the
midline of the back, exposing the paravertebral muscles.
These muscles were dissected away, exposing T5–T8 verteb-
rae. The spinal cord was exposed via a two-level T6–T7
laminectomy, and SCI was produced by extradural compres-
sion of the spinal cord using an aneurysm clip with a closing
force of 24 g. In all of the injured groups, the spinal cord was
compressed for 1 min. Sham-injured animals were only
subjected to laminectomy.
After surgery, 1 ml of saline was administered subcuta-
neously to replace the blood volume lost during the surgery.
During recovery from anaesthesia, the mice were placed on a
warm heating pad and covered with a warm towel. The mice
were singly housed in a temperature-controlled room at
27 1C for a survival period of 10 days. Food and water were
provided to the mice ad libitum. During this period, the
bladders of the animals were manually voided twice a day
until the mice were able to regain normal bladder function.
Experimental groups
Mice were randomly allocated into the following groups: (1)
SCIþ vehicle (saline solution), subjected to SCI and given
vehicle i.p. 1 h and 6 h after injury (n¼50 mice, Table 1); (2)
SCIþ zileuton, subjected to SCI and given zileuton
(50 mg kg1 weight in saline solution p.o) 1 h and 6 h after
injury (n¼50 mice, Table 1); (3) SCIþmontelukast, sub-
jected to SCI and given montelukast (5 mg kg1 weight in
saline i.p.) 1 and 6 h after injury (n¼50 mice, Table 1); (4)
Table 1 Number of animals used in the different experiments
Animal
number
(n)
Experiment type
10 Histological examination, immunohistochemical localization of
MPO, TNF-a, Bax, Bcl-2 and FAS ligand, Annexin-V evaluation
and TUNEL assay.
10 Myeloperoxidase activity
10 Measurement of TNF-a
10 Western blot analysis for Bax, Bcl-2, COX-2, pERK-1/2, ERK-2
and b-actin
10 Motor function
10 Measurement of PGE2 and LTB4
Abbreviation: ERK, extracellular signal-regulated kinase; LTB4, leukotriene B4;
MPO, myeloperoxidase; PGE2, prostaglandin E2; TNF-a, tumour necrosis-a;
TUNEL, terminal deoxynucleotidyltransferase-mediated UTP end labelling.
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shamþ vehicle, subjected to a T6–T7 laminectomy and given
vehicle i.p. 1 and 6 h after laminectomy (n¼50 mice,
Table 1); (5) shamþ zileuton, subjected to a T6–T7 laminect-
omy and given zileuton (50 mg kg1, p.o.) 1 and 6 h after
laminectomy (n¼50 mice, Table 1) and (6) shamþ
montelukast, subjected to a T6–T7 laminectomy and given
montelukast (5 mg kg1, i.p.) 1 h and 6 h after laminectomy
(n¼50 mice, Table 1). In the experiments measuring motor
function, the animals were treated with drugs 1 and 6 h after
SCI daily until day 9.
At different time points, the animals (n¼10 mice from
each group for each time point) were killed in order to
evaluate the various parameters described below.
The dose of zileuton (50 mg kg1) was chosen according to
our earlier studies (Failla et al., 2006; Mazzon et al., 2006),
while the selected dose of montelukast (5 mg kg1) was
chosen on the basis of published data (Saito et al., 2004; Lee
et al., 2007).
Histological examination
Spinal cord biopsies were taken at 24 h following trauma.
Tissue segments containing the lesion (1 cm on each side of
the lesion) were paraffin embedded and cut into 5-mm-thick
longitudinal sections. The tissue sections were deparaffinized
with xylene, stained with haematoxylin/eosin and examined
by light microscopy (Dialux 22 Leitz). The segments of each
spinal cord were evaluated by an experienced histopatholo-
gist and all the histological studies were performed without
knowledge of the treatments.
Grading of motor disturbance
The motor function of mice subjected to compression
trauma was assessed once a day for 10 days after injury.
Recovery from motor disturbance was graded using the
modified murine Basso, Beattie and Bresnahan (BBB) (Basso
et al., 1995) hindlimb locomotor-rating scale (Joshi and
Fehlings, 2002a, b). The following criteria were considered:
0¼no hindlimb movement; 1¼ slight (o50% range of
motion) movement of one to two joints; 2¼ extensive
(450% range of motion) movement of one joint and slight
movement of one other joint; 3¼ extensive movement of
two joints; 4¼ slight movement in all three joints; 5¼ slight
movement of two joints and extensive movement of one
joint; 6¼ extensive movement of two joints and slight
movement of one joint; 7¼ extensive movement of all three
joints; 8¼ sweeping without weight support or plantar
placement and no weight support; 9¼plantar placement
with weight support in stance only or dorsal stepping with
weight support; 10¼occasional (0–50% of the time) weight-
supported plantar steps and no coordination (front/hindlimb
coordination); 11¼ frequent (50–94% of the time) to con-
sistent (95–100% of the time) weight-supported plantar steps
and no coordination; 12¼ frequent to consistent weight-
supported plantar steps and occasional coordination; 13¼
frequent to consistent weight-supported plantar steps and
frequent coordination; 14¼ consistent weight-supported
plantar steps, consistent coordination and predominant
paw position is rotated during locomotion (lift off and
contact) or frequent plantar stepping, consistent coordina-
tion and occasional dorsal stepping; 15¼ consistent plantar
stepping and coordination, no/occasional toe clearance, paw
position is parallel at initial contact; 16¼ consistent plantar
stepping and coordination (front/hindlimb coordination)
and frequent toe clearance and predominant paw position
is parallel at initial contact and rotated at lift off;
17¼ consistent plantar stepping and coordination and
frequent toe clearance and predominant paw position is
parallel at initial contact and lift off; 18¼ consistent plantar
stepping and coordination and consistent toe clearance and
predominant paw position is parallel at initial contact and
rotated at lift off; 19¼ consistent plantar stepping and
coordination and consistent toe clearance and predominant
paw position is parallel at initial contact and lift off;
20¼ consistent plantar stepping, coordinated gait, consis-
tent toe clearance, predominant paw position is parallel at
initial contact and lift off and trunk instability;
21¼ consistent plantar stepping, coordinated gait, consis-
tent toe clearance, predominant paw position is parallel at
initial contact and lift off and trunk stability.
Myeloperoxidase activity
Myeloperoxidase (MPO) activity, an indicator of polymorpho-
nuclear leucocyte (PMN) accumulation, was determined
as previously described (Mullane et al., 1985) 24 h after SCI.
This time was chosen in agreement with other studies
(Hamada et al., 1996). At the specified time following SCI,
spinal cord tissues were obtained and weighed and each
piece homogenized in a solution containing 0.5% (w/v)
hexadecyltrimethyl-ammonium bromide dissolved in
10 mM potassium phosphate buffer (pH 7) and centrifuged
for 30 min at 20 000 g at 4 1C. An aliquot of the supernatant
was then allowed to react with a solution of 1.6 mM
tetramethylbenzidine and 0.1 mM H2O2. The rate of change
in absorbance was measured spectrophotometrically at
650 nm. MPO activity was defined as the quantity of enzyme
degrading 1mmol of peroxide min1 at 37 1C and was
expressed in U g1 of wet tissue.
Immunohistochemical localization of MPO, TNF-a, Bax, Bcl-2
and FAS ligand
At 24 h after SCI, the tissues were fixed in 10% (w/v)
phosphate-buffered saline (PBS)-buffered formaldehyde and
8 mm sections were prepared from paraffin-embedded tissues.
After deparaffinization, endogenous peroxidase was
quenched with 0.3% (v/v) hydrogen peroxide in 60% (v/v)
methanol for 30 min. The sections were permeabilized with
0.1% (w/v) Triton X-100 in PBS for 20 min. Nonspecific
adsorption was minimized by incubating the section in 2%
(v/v) normal goat serum in PBS for 20 min. Endogenous
biotin or avidin binding sites were blocked by sequential
incubation for 15 min with biotin and avidin, respectively.
Sections were incubated overnight with anti-MPO, anti-
TNF-a, anti-Bax or anti-FAS ligand rabbit polyclonal anti-
body, and anti-Bcl-2 polyclonal antibody rat (1:500 in PBS, v/
v). Sections were washed with PBS and incubated with
secondary antibody. Specific labelling was detected with a
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biotin-conjugated goat anti-rabbit IgG and avidin-biotin
peroxidase complex. To verify the binding specificity for
MPO, TNF-a, Bax, Bcl-2 and FAS ligand, some sections were
also incubated with only the primary antibody (no second-
ary) or with only the secondary antibody (no primary). In
these situations, no positive staining was found in the
sections, indicating that the immunoreactions were positive
in all of the experiments carried out.
Immunohistochemical photographs (n¼5 photos from
each sample collected from each mice in each experimental
group) were assessed by densitometry as described previously
(Shea, 1994) by using Optilab Graftek software on a
Macintosh personal computer.
Measurement of TNF-a
Portions of spinal cord tissues, collected at 24 h after SCI,
were homogenized as previously described in PBS containing
2 mM of phenylmethyl sulphonyl fluoride to evaluate TNF-a
tissue levels. The assay was carried out by using a colori-
metric, commercial kit (Calbiochem-Novabiochem Corpora-
tion, CA, USA) according to the manufacturer’s instructions.
All TNFa determinations were performed in duplicate serial
dilutions.
Annexin-V evaluation
The binding of annexin-V fluorescein isothiocyanate (FITC)
(Ann-V) to externalized phosphatidylserine was used as a
measurement of apoptosis in spinal cord tissue section with
an Ann-V-propidium iodide (PI) apoptosis detection kit
(Santa Cruz, DBA, Milan, Italy) according to the manufac-
turer’s instructions. Briefly, normal viable cells in culture will
stain negative for annexin-V FITC and negative for PI. Cells
induced to undergo apoptosis will stain positive for annexin-
V FITC and negative for PI as early as 1 h after stimulation
(Schutte et al., 1998). Cells in later stages of apoptosis and
necrotic cells will both stain positive for annexin-V FITC and
PI. Sections were washed as before, mounted with 90%
glycerol in PBS, and observed with an LSM 510 Zeiss laser
confocal microscope equipped with a  40 oil objective.
Terminal deoxynucleotidyltransferase-mediated UTP end labelling
assay
These assays were conducted using a terminal deoxynucleo-
tidyltransferase-mediated UTP end labelling assay (TUNEL)
detection kit according to the manufacturer’s instruction
(Apotag, HRP kit; DBA srl). In brief, sections were incubated
with 15 mg ml1 proteinase K for 15 min at room temperature
and then washed with PBS. Endogenous peroxidase was
inactivated by 3% H2O2 for 5 min at room temperature and
then washed with PBS. Sections were immersed in TdT buffer
containing deoxynucleotidyl transferase and biotinylated
deoxyuridine triphosphate in TdT buffer, incubated in a
humid atmosphere at 37 1C for 90 min, and then washed
with PBS. The sections were incubated at room temperature
for 30 min with anti-horseradish peroxidase-conjugated
antibody, and the signals were visualized with diamino-
benzidine.
Total protein extraction and western blot analysis for Bax, Bcl-2,
COX-2, pERK-1/2, ERK-2 and b-actin
Tissue samples from SCI-injured animals (n¼10) after 24 h
were homogenized in a buffer containing 20 mM HEPES pH
7.6, 1.5 mM MgCl2, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride,
15 mg ml1 trypsin inhibitor, 3mg ml1 pepstatin, 2mg ml1
leupeptin, 40 mM benzamidine, 1% Nonidet P-40, 20%
glycerol and 50 mM NaF. The homogenates were centrifuged
at 10 000 g for 15 min and at 4 1C, and the supernatant was
collected and protein concentration was determined by
Bio-Rad protein assay (Bio-Rad Laboratories GmbH, Munch-
en). Equal amounts of protein (50 mg) were mixed with gel
loading buffer (50 mM Tris, 10% sodium dodecyl sulfate,
10% glycerol, 10% 2-mercaptoethanol and 2 mg ml1 bromo-
phenol) in a ratio of 1:1, boiled for 3 min and centrifuged at
10 000 g for 10 min. Each sample was loaded and electro-
phoresed on a 10% sodium dodecyl sulfate–polyacrylamide
gel. The proteins were transferred on to nitrocellulose
membranes. The membranes were blocked with 0.1% PBS-
Tween containing 5% non-fat dry milk for ERK-2, Bax, Bcl-2,
COX-2 and b-actin, whereas with 0.1% PBS-Tween contain-
ing 5% non-fat dry milk and 50 mM NaF for pERK-1/2. After
the blocking, the membranes were incubated with the
relative primary antibody overnight at 4 1C. Rabbit mono-
clonal antibodies, anti-Bax, anti-bcl2 (Santa Cruz Biotech-
nology) and anti-COX-2 (Upstate cell signalling solutions,
New York), and mouse monoclonal antibodies, anti-ERK-2
(Santa Cruz Biotechnology), were diluted 1:1000 in 0.1%
PBS-Tween, 5% non-fat dry milk; mouse monoclonal anti-
body anti-pERK1/2 (Santa Cruz Biotechnology) was diluted
1:1000 in 0.1% PBS-Tween, 5% non-fat dry milk, 50 mM NaF;
mouse monoclonal antibody anti-b-actin (Sigma-Aldrich,
Milan, Italy) was diluted 1:10 000 in 0.1% PBS-Tween, 5%
BSA. After the incubation, the membranes were washed six
times with 0.1% PBS-Tween and were incubated for 1.5 h at
room temperature with horseradish peroxidase-conjugated
anti-mouse secondary antibodies (Dako Cytomation,
Denmark) diluted 1:1000 in 0.1% PBS-Tween containing
5% non-fat dry milk. The membranes were washed and
protein bands were detected by an enhanced chemilumines-
cence system (Amersham Pharmacia, Amersham Biosciences,
UK). Densitometric analysis was performed with a Fluor S
quantitative imaging system (Bio-Rad Laboratories).
Determination of PGE2 and LTB4 levels in mouse spinal cords
The spinal cords were collected at 24 h after SCI from the
animals (two to six spinal cords were pooled together) and
immediately homogenized in methanol. The mediators in
the tissues were extracted in 5 ml methanol for 3–5 days at
80 1C. To remove the tissue residues, the extracts were
centrifuged at 1800 g for 20 min at 4 1C. Then the sample
solutions were dried to remove methanol. The dried samples
were suspended in an assay buffer that was supplied with
each ELISA kit (Assay Designs). To determine the levels
of PGE2 and LTB4 within the sensitive (that is, linear)
ranges of the standard curves, the samples were diluted a
further 1- to 20-fold and assayed at multiple dilutions
(Marusic et al., 2005).
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Statistical procedures
All values in the figures are expressed as mean±s.e.mean of n
observations. For the in vivo studies, n represents the number
of animals studied. In the experiments involving histology or
immunohistochemistry, the figures shown are representative
at least three experiments (histological or immunohistochem-
ical staining) performed on different experimental days on the
tissues section collected from all the animals in each group
(n¼10). The results were analysed by one-way ANOVA
followed by a Bonferroni post hoc test for multiple compar-
isons; Po0.05 was considered significant. Basso, Beattie and
Bresnahan scale data were analysed by the Mann–Whitney test
and considered significant when Po0.05.
Drugs and chemical reagents
Zileuton and montelukast were obtained from Sequoia
Research Products (Oxford, UK). Biotin and avidin were
obtained from DBA (Milan, Italy). The antibodies against
Bax, bcl2, pERK1/2 and ERK-2 were obtained from Santa
Cruz Biotechnology Inc. (Milan, Italy). The antibody against
COX-2 was from Upstate (NY). All other reagents and
compounds used were obtained from Sigma-Aldrich.
Results
Effects of zileuton and montelukast on the severity of spinal cord
trauma
Twenty-four hours after the trauma, there was significant
damage to the spinal cord at the perilesional zone, as
assessed by the presence of oedema, as well as an alteration
of the white matter observed in SCIþ vehicle-treated mice
(Figure 1a) when compared with spinal cord tissue collected
from shamþ vehicle-treated mice. A significant protection of
the SCI was observed in the tissue collected from
SCIþ zileuton-treated mice (50 mg kg1 1 and 6 h after
injury) (Figure 1b) or SCIþmontelukast-treated-mice
(5 mg kg1 weight 1 and 6 h after injury) (Figure 1c).
To evaluate whether histological damage to the spinal cord
was associated with a loss of motor function, the modified
Basso, Beattie and Bresnahan hindlimb locomotor-rating
scale score was evaluated. Although motor function was
only slightly impaired in sham mice groups (Figure 2a),
SCIþ vehicle-treated mice had significant deficits in hin-
dlimb movement (Figure 2b). In contrast, a significant
(Po0.001) amelioration of hindlimb motor disturbances
was observed in SCIþ zileuton-treated or montelukast-
treated-mice (Figure 2b).
Effects of zileuton and montelukast on neutrophil infiltration
MPO activity was significantly (Po0.001) elevated at 24 h
after SCI in vehicle-treated mice compared with spinal
cord tissue collected from shamþ vehicle-treated mice
(Figure 3d). In zileuton- or montelukast-treated mice, spinal
cord MPO activity, at 24 h, was significantly (Po0.001)
attenuated compared with those of SCIþ vehicle-treated
animals. In addition, tissue sections obtained at 24 h from
SCIþ vehicle-treated mice demonstrated positive staining for
MPO, mainly localized in the infiltrated inflammatory cells
in the injured area (Figures 3a and 4). Moreover, in mice
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Figure 1 Effect of zileuton and montelukast on histological alterations of the spinal cord tissue 24 h after injury. (a) Twenty-four hours after
trauma, a significant damage to the spinal cord from SCIþ vehicle-treated mice at the perilesional area was assessed by the presence of
oedema and alteration of the white matter. A significant protection from the SCI was observed in the tissue collected from SCIþ zileuton (b) or
montelukast-treated mice (c). This figure is representative of at least three experiments performed on different experimental days. wm, white
matter; gm, grey matter. No histological alteration was observed in the spinal cord tissues from sham-operated mice (data not shown). SCI,
spinal cord injury.
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treated with zileuton (Figures 3b and 4) or montelukast
(Figures 3c and 4), the staining for MPO was visibly reduced
in comparison with that observed in SCIþ vehicle-treated
mice. There was no staining for MPO in spinal cord
tissues obtained from the sham group of mice (data not
shown).
Effect of zileuton and montelukast on TNF-a levels
Immunohistological analysis of the spinal cord after SCI was
performed to determine whether zileuton and montelukast
may modulate the secondary inflammatory reaction also
through the regulation of the secretion of cytokines, such as
TNF-a. A substantial increase of TNF-a (Figures 4, 5a and d)
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Figure 2 Effect of zileuton and montelukast on hindlimb motor dysfunction after SCI. The degree of motor dysfunction of (a) Sham groups
and (b) SCI groups was assessed every day for 10 days after SCI induction by Basso–Beattie–Bresnahan criteria (Basso et al., 1995). Treatment
with zileuton or montelukast reduces the loss of motor function after SCI. Values shown are mean±s.e.mean of 10 mice for each group.
*Po0.01 versus SCIþ vehicle. SCI, spinal cord injury.
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Figure 3 Effect of zileuton and montelukast on immunohistochemical localization and activity of MPO. A significant positive staining and a
significant increase of MPO activity was observed in the spinal cord tissues collected from SCIþ vehicle-treated mice (a, d). In mice treated with
zileuton (b, d) or montelukast (c, d), the MPO staining and activity was visibly and significantly reduced in comparison with the SCIþ vehicle-
treated mice. No positive staining for MPO was observed in spinal cord tissues collected from sham-operated mice (data not shown). Image is
representative of at least three experiments performed on different experimental days. Data are means±s.e.mean of 10 mice for each group.
*Po0.01 versus sham-operated mice; 1Po0.01 versus SCIþ vehicle-treated mice. wm, white matter; gm, grey matter; MPO, myeloperoxidase;
SCI, spinal cord injury.
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formation was found in spinal cord samples collected from
SCIþ vehicle-treated mice at 24 h after SCI. Spinal cord levels
of TNF-a were significantly attenuated in mice treated with
zileuton or montelukast (Figures 4 and 5b–d). There was no
staining for TNF-a in spinal cord obtained from sham groups
of mice (data not shown).
Effect of zileuton and montelukast on apoptosis in spinal cord
tissue after injury
To test whether the tissue damage was associated with
apoptotic cell death, we measured annexin V staining in the
spinal cord tissues. Almost no apoptotic cells were detectable
in the spinal cord tissue from sham groups of mice (data not
shown). However, at 24 h after SCI, tissues obtained from
SCIþ vehicle-treated mice demonstrated a marked appear-
ance of positive staining for annexin-V (Figure 6a), indicative
of cells undergoing apoptosis. In addition, some cells showed
a positive intracellular staining to PI, an index of cells in the
late stage of apoptosis (Figure 6a1). On the contrary, spinal
cord tissues section from mice treated with zileuton or
montelukast demonstrated no cells in the earlier stage of
apoptosis (Figures 6b and c, respectively) and a decreased
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presence of cells (positive for PI) in the later stages of
apoptosis (Figures 6b1 and c1, respectively). The Figures 6a2,
b2 and c2 staining are the combination of a and a1, b and b1,
and c and c1, respectively.
Moreover, to confirm whether tissue damage was asso-
ciated with apoptotic cell death, we also measured TUNEL-
like staining in the perilesional spinal cord tissue. Almost no
apoptotic cells were detectable in the spinal cord tissue from
sham-operated mice (data not shown). At 24 h after the
trauma, tissues obtained from SCIþ vehicle-treated mice
demonstrated a marked appearance of dark-brown (TUNEL-
positive) apoptotic cells and intercellular apoptotic frag-
ments (Figure 7a). In contrast, tissues obtained from mice
treated with zileuton (Figure 7b) or montelukast (Figure 7c)
contained a smaller number of TUNEL-positive cells. Section
D demonstrates the positive staining in the Kit-positive
control tissue.
Immunohistological staining for FAS Ligand in the spinal
cord was also determined 24 h after injury. Sections of spinal
cord from shamþ vehicle-treated mice did not stain for FAS
Ligand (data not shown), whereas spinal cord sections
obtained from SCIþ vehicle-treated mice exhibited positive
staining for FAS Ligand (Figures 4 and 8a) mainly localized in
inflammatory cells as well as in nuclei of Schwann cells in
the white (wm) and grey (gm) matter of the spinal cord
tissues. Treatment of mice subjected to SCI with zileuton
(Figures 4 and 8b) or montelukast (Figures 4 and 8c) reduced
the degree of positive staining for FAS Ligand in the spinal
cord. There was no staining for FAS Ligand in spinal cord
tissues obtained from the sham group of mice (data not
shown).
Effect of zileuton and montelukast on Bax and Bcl-2
immunohistochemistry and expression
Spinal cord tissues were taken at 24 h after SCI to determine
the immunohistological staining for Bax and Bcl-2. Sections
of spinal cord from shamþ vehicle-treated mice showed a
negative stain for Bax (data not shown), whereas those
obtained from SCIþ vehicle-treated mice exhibited positive
staining for Bax (Figures 4 and 9a). The degree of positive
staining for Bax was reduced in spinal cord tissues collected
Figure 6 Effect of zileuton and montelukast on apoptosis. At 24 h after SCI, spinal cord tissues obtained from SCIþ vehicle-treated mice
demonstrated a marked appearance of positive stain for annexin V FITC (a), an index of cells that are induced to undergo apoptosis. Some cells
showed a positive intracellular staining to PI (a1), an index of cells in the late stage of apoptosis. On the contrary, spinal cord tissues section
from mice treated with zileuton or montelukast demonstrate no cells in the earlier stage (b and c, respectively) of apoptosis and fewer cells
(positive to PI) in the later stages of apoptosis (b1 and c1, respectively). (a2, b2, and c2) Staining combination of a and a1, b and b1, and c and
c1, respectively. The figure is representative of at least three experiments performed on different experimental days. FITC, fluorescein
isothiocyanate; PI, propidium iodide SCI, spinal cord injury.
Zileuton and montelukast in spinal cord injury
T Genovese et al 575
British Journal of Pharmacology (2008) 153 568–582
a b
c d
Figure 7 Effect of zileuton and montelukast on TUNEL staining in perilesional spinal cord tissue. At 24 h after the trauma, tissues obtained
from SCIþ vehicle-treated mice demonstrated a marked appearance of dark-brown apoptotic cells and intercellular apoptotic fragments (a). In
contrast, tissues obtained from mice treated with zileuton (b) or montelukast (c) demonstrated a small number of apoptotic cells or fragments.
Almost no apoptotic cells were detectable in the spinal cord tissue of sham-operated mice (data not shown). Panel d demonstrates the positive
staining in the Kit-positive control tissue. The figure is representative of at least three experiments performed on different experimental days.
SCI, spinal cord injury; TUNEL, terminal deoxynucleotidyltransferase-mediated UTP end labelling assay.
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Figure 8 Effect of zileuton and montelukast on immunohistological staining for FAS Ligand. At 24 h after the trauma spinal cord sections
obtained from SCIþ vehicle-treated mice exhibited positive staining for FAS Ligand (a) mainly localized in inflammatory cells as well as in nuclei
of Schwann cells in the white (wm) and grey (gm) matter of the spinal cord tissues. Treatment of mice subjected to SCI with zileuton (b) or
montelukast (c) reduced the degree of positive staining for FAS Ligand in the spinal cord. There was no staining for FAS Ligand in spinal cord
tissues obtained from the sham group of mice (data not shown). SCI, spinal cord injury.
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from mice treated with zileuton (Figures 4 and 9b) or
montelukast (Figures 4 and 9c). Moreover, the appearance
of Bax in homogenates of spinal cord tissues was investigated
by western blot at 24 h after SCI. A basal level of Bax was
detectable in the homogenized spinal cord tissues from
shamþ vehicle-treated animals (Figure 9d). Bax levels were
significantly increased in the spinal cord tissues of
SCIþ vehicle-treated mice (Figure 9d). The treatment of
mice with zileuton or montelukast prevented the SCI-
mediated Bax expression (Figure 9d).
In addition, sections of spinal cord from sham-operated
mice demonstrated positive staining for Bcl-2 (data not
shown). Spinal cord sections obtained from SCIþ vehicle-
treated mice exhibited less staining for Bcl-2 (Figures 4 and
10a). The loss of positive staining for Bcl-2 was significantly
reduced in spinal cord tissues collected from mice treated
with zileuton (Figures 4 and 10b) or montelukast (Figures 4
and 10c). The same results were observed by western blot
analysis. In fact, a high basal level of Bcl-2 expression was
detected in spinal cord homogenates from the tissue of
shamþ vehicle-treated mice (Figure 10d). The Bcl-2 expres-
sion was significantly diminished in whole extracts obtained
from spinal cord tissues of vehicle-treated mice 24 h after
SCI. Treatment of mice with zileuton or montelukast
significantly increased the expression of Bcl-2 (Figure 10d).
Effect of zileuton and montelukast on COX-2 expression and on
activation of MAPK signal transduction pathway
As phosphorylation of ERK1/2 results in expression of
genes, such as that encoding for COX-2, mediating the
inflammatory responses characteristic of SCI, the expres-
sion of this enzyme and ERK1/2 phosphorylation in
homogenates of spinal cord tissues was investigated by
western blot at 24 h after SCI. A basal level of COX-2 was
detectable in the homogenized spinal cord tissues from
sham-operated animals (Figure 11). COX-2 levels were
significantly increased in the spinal cord tissues of
SCIþ vehicle-treated mice. The treatment of mice with
zileuton or montelukast reduced the SCI-mediated COX-2
expression (Figure 11).
To investigate whether the increase in COX-2
expression, observed in our experimental conditions,
corresponded to an activation of signal transduction
pathways involved in the regulation of COX-2 expression,
we analysed the activation of MAPK pathways in
particular the phosphorylation of ERK1/2 24 h after SCI.
As shown in Figure 11, pERK1/2 levels were significantly
increased in the spinal cord tissues of SCIþ vehicle-treated
mice. The treatment of mice with zileuton or mon-
telukast significantly reduced the level of pERK1/2
(Figure 12).
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Figure 9 Effect of zileuton and montelukast on Bax levels. At 24 h, SCI caused an increase of Bax expression in vehicle-treated mice (a). On
the contrary, the degree of positive staining for Bax was reduced in spinal cord tissues collected from mice treated with zileuton (b) or
montelukast (c). No positive staining for Bax was observed in the tissue section from sham-operated mice (data not shown). Figure is
representative of at least three experiments performed on different experimental days. (d) Western blot analysis of extracts of spinal cord tissue
collected at 24 h after injury. Basal levels of Bax was present in the tissue from sham-operated mice. Bax band is more evident in the tissue from
SCIþ vehicle-treated mice. The treatment with zileuton or montelukast reduced Bax levels. Data were normalized on the basis of b-actin levels.
Densitometric analysis of protein expression represents the mean±s.e.mean of 10 spinal cord tissues. 1Po0.01 versus sham-operated mice;
*Po0.05 versus SCIþ vehicle. wm, white matter; gm, grey matter; SCI, spinal cord injury.
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Effect of zileuton and montelukast on the production of PGE2 and
LTB4
An increase of PGE2 and LTB4 formation was found in spinal
cord samples collected from SCIþ vehicle-treated mice at
24 h after SCI. Spinal cord levels of PGE2 and LTB4 were
significantly attenuated in mice treated with zileuton or
montelukast (Figures 13a and b).
Discussion
The greater part of SCI in civilian life arises from fracture or
dislocation of the vertebral column. Modern neuroscience
techniques have led investigators to a better understanding
of the importance of both primary (passive) and secondary
(active) events in causing progressive loss of neural tissue.
There are three stages of SCI where pharmacotherapy may
have a therapeutic role (Greene et al., 1994, 1996). In the
acute stage, treatments aimed towards diminishing the
immune or inflammatory response, excitotoxicity and lipid
peroxidation may limit secondary mechanisms of injury
(Bracken et al., 1990). In the subacute stage, initiation of
neurotrophic therapies may help to reconstitute the
damaged tissue (Geisler et al., 1991, 1992). Interventions in
the chronic stage of SCI will more than likely involve
neurotrophic substances in combination with tissue or
mesenchymal stem cell transplantation (Cheng et al., 1996;
Bregman et al., 1997a, b, 1998; Diener and Bregman,
1998a, b). Nevertheless, only limited therapeutic measures
are currently available for the treatment of SCI and only an
extensive knowledge of the molecular and cellular mechan-
isms involved in the etiopathogenesis of SCI will lead to a
crucial therapeutic intervention.
In this report, we demonstrate that a 5-LO inhibitor,
zileuton, and a Cys-LT1 antagonist, montelukast, exert
beneficial effects in a mouse model of SCI that mimics the
human pathology. The main findings of the current study
are that treatment with zileuton or montelukast improved
motor recovery and reduced tissue injury, cell infiltration at
the injured site, apoptotic cell death, ERK1/2 activation, and
TNF-a and COX-2 levels in the injured tissue.
These results not only confirm our previous report
showing that mice with a targeted deletion of the 5-LO gene
(5-LO-deficient mice) are protected against experimental SCI
(Genovese et al., 2005), but underline the role of Cys-LTs,
although the role of other 5-LO metabolites cannot be
excluded. (Sugaya et al., 2000; Bertolini et al., 2002; Hensley
et al., 2006). In fact, it has been suggested that an over-
expressed/overactive 5-LO pathway may lead to neurode-
generation by promoting neutrophil migration. It is well
known that LTB4 and Cys-LTs are potent chemotactic factors
involved in recruitment of cells at the inflammation site
(Ford-Hutchinson et al., 1980; Levine et al., 1984; Bisgaard
and Kristensen, 1985; Virchow et al., 2001). In particular,
Cys-LTs exert their effects through binding Cys-LT1 receptors
(Blain and Sirois, 2000). Moreover, in mice treated with
zileuton or montelukast, a good correlation between the
significant reduction of leucocyte infiltration, LT production
and reduced tissue damage, evaluated by histological
examination, was observed. In addition, mice treated
with zileuton or montelukast showed an improvement in
motor function.
Experimental evidence suggests that LTs may promote
inflammation also through the regulation of other pro-
inflammatory factors, such as TNF-a (Ichiyama et al., 2007;
Tugtepe et al., 2007) and COX-2 (Rossi et al., 2005), which
seem to be involved in neurodegeneration. Moreover, it has
been demonstrated that TNF-a and COX-2 are clearly
involved in the pathogenesis of experimental SCI in rats
and mice (Yan et al., 2001; Bao et al., 2004; Adachi et al.,
2005). In the present study, we have demonstrated, by
immunohistochemistry, a significant increase of positive
staining for TNF-a in SCIþ vehicle mice compared with
sham-operated animals. With regard to COX-2, we have
recently demonstrated that in a model of inflammation in
vitro, such as elicited peritoneal macrophages from mice
activated with lipopolysaccharide/interferon-g, LTC4, but
not the other LTs, increased COX-2 expression and PG
production (Rossi et al., 2005). The signal transduction
mechanism involved in this upregulation was related to
activation of the MAPK family of protein serine/threonine
kinases, which includes ERK-1 and ERK-2 (Garrington and
Johnson, 1999). In particular, the MAPK activation observed
in the study was correlated with the phosphorylation of
ERK1/2 through activation of the Cys-LT1 receptor. Similar
results have been obtained in the present study as demon-
strated by the decrease of COX-2, PGE2 and pERK1/2 levels in
SCIþ zileuton- or SCIþmontelukast-treated mice, compared
to SCIþ vehicle-treated mice.
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Figure 13 Effect of zileuton and montelukast on levels of PGE2 and
LTB4 in spinal cord. SCI caused, at 24 h, an increase in the release of
PGE2 (a) and LTB4 (b) in spinal cord tissues. Treatment with zileuton
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The LTs are regulatory signals for neural cell proliferation
and differentiation (Wada et al., 2006) and apoptosis is an
important mediator of secondary damage after SCI (Beattie
et al., 2002). In this study, as observed previously in 5-LO
knockout mice subjected to SCI (Genovese et al., 2005), the
inhibition of the 5-LO pathway, by the use of zileuton or
blockade of Cys-LT action by montelukast, reduced cell
apoptosis (as assessed by annexin V, TUNEL and Fas ligand
staining) after SCI induction in spinal cord tissue. This effect
could be due to the inhibition of neutrophil infiltration. In
other studies, decreased neutrophil infiltration due to the
absence of 5-LO (Cuzzocrea et al., 2005) may have con-
tributed to the attenuation of pro-apoptotic mediators, such
as reactive oxygen species (Xu et al., 2005). Moreover, it is
well known that Bax, a proapoptotic protein, plays an
important role in the development of cell death (Chittenden
et al., 1995) and in central nervous system injury (Bar-Peled
et al., 1999). Likewise, it has been shown that the adminis-
tration of Bcl–xL fusion protein (Bcl-2 is the most expressed
antiapoptotic molecule in the adult central nervous system)
into injured spinal cords significantly increased neuronal
survival, suggesting that SCI-induced changes in Bcl–xL
contribute considerably to neuronal death (Nesic-Taylor
et al., 2005). On the basis of this evidence, we have identified
apoptotic transcriptional changes in mice subjected to SCI.
These include upregulation of proapoptotic Bax and down-
regulation of antiapoptotic Bcl-2, as assessed by Western blot
assay and immunohistochemical staining. In particular, we
demonstrated that zileuton and montelukast reduced the
SCI-induced transcriptional changes related to apoptosis.
In conclusion, this study demonstrated that zileuton and
montelukast improved motor recovery and reduced tissue
injury, cell infiltration at the injured site, apoptotic cell
death, pERK1/2 expression, and TNF-a and COX-2 level in
injured tissue. Taken together, these results provide evidence
that zileuton and montelukast were able to produce a
substantial reduction of inflammatory events associated
with experimental SCI and underline the important role of
5-LO and Cys-LTs in this model.
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